PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease Reportsretinoblastoma
MeSH D012175 - retinoblastoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D019572:Retinal neoplasms
0 Companies
0 Drugs
Success rate
D015785:Hereditary eye diseases
0 Companies
0 Drugs
Success rate
D018302:Neuroepithelial neoplasms
0 Companies
0 Drugs
Success rate
D012175: 
Retinoblastoma
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaCyclophosphamide Neosar  1993-04-29   
IngenusCyclophosphamide Cyclophosphamide 2036-02-15 2020-07-30   
CiplaCyclophosphamide Cyclophosphamide  2019-01-18   
Alembic PharmaceuticalsCyclophosphamide Cyclophosphamide  2022-11-10   
Amneal PharmaceuticalsCyclophosphamide Cyclophosphamide  2018-05-25   
ANI PharmaceuticalsCyclophosphamide Cyclophosphamide  2018-03-19   
Hikma PharmaceuticalsCyclophosphamide Cyclophosphamide  2013-09-16   
Roxane LaboratoriesCyclophosphamide Cyclophosphamide  1999-08-17   
Eugia Pharma SpecialtiesCyclophosphamide Cyclophosphamide 2035-06-26 2021-08-25   
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
63%
19/30
Phase 2
48%
13/27
Phase 3
20%
5/25
Approved: 2Overall Success rate: 6%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
1
2
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use